Cancers
April 27, 2024
Val Bellman
9 citations
Despite the legalization of psilocybin therapy for depression in terminal illnesses such as advanced cancer through Oregon’s Measure 109 in 2020, significant challenges have impeded its implementation. This review synthesizes the empirical data supporting the utilization of psilocybin therapy for addressing cancer-related depression, including an evaluation of its purported benefits and...
BMC Psychiatry
April 25, 2024
Tobias P. Whelan, Eileen Daly, Nicolaas A.j. Puts et al.
8 citations
The underlying neurobiology of the complex autism phenotype remains obscure, although accumulating evidence implicates the serotonin system and especially the 5HT2A receptor. However, previous research has largely relied upon association or correlation studies to link differences in serotonin targets to autism. To directly establish that serotonergic signalling is involved in a candidate brain...
Fungal biology and biotechnology
April 25, 2024
Paula Sophie Seibold, Sebastian Dörner, Janis Fricke et al.
8 citations
Although Basidiomycota produce pharmaceutically and ecologically relevant natural products, knowledge of how they coordinate their primary and secondary metabolism is virtually non-existent. Upon transition from vegetative mycelium to carpophore formation, mushrooms of the genus Psilocybe use L-tryptophan to supply the biosynthesis of the psychedelic tryptamine alkaloid psilocybin with the...
Journal of Eating Disorders
April 24, 2024
Amanda E. Downey, Anita V. Chaphekar, Joshua Woolley et al.
13 citations
Clinical trials using psilocybin therapy to treat anorexia nervosa (AN) are currently underway. The safety and tolerability of psilocybin is of utmost importance in individuals with AN who may present unique medical vulnerabilities. The purpose of this review is to describe how the common physiologic adverse effects of psilocybin may impact medical complications experienced by individuals with...
Scientific Reports
April 23, 2024
Berit Singer, Daniel Meling, Matthias Hirsch-Hoffmann et al.
The original version of this Article contained an error in the name of author Berit Singer which was incorrectly given as Singer Berit.
April 23, 2024
David A. Gorelick
Psilocybin shows promise for treatment-resistant depression, with rapid onset and long-lasting effects. Psilocybin treatment currently involves extensive psychotherapy sessions, which may limit accessibility and increase costs. The efficacy of psilocybin without concurrent psychotherapy is unknown. Long-term safety risks of psilocybin treatment remain uncertain.
Psychiatric News
April 23, 2024
Terri D’arrigo
announced in April that the Food and Drug Administration (FDA) approved the antipsychotic Fanapt (iloperidone) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. Iloperidone has been approved for the acute treatment of schizophrenia since 2009. The approval was based on a phase 3 clinical trial of 414 adults with a history of bipolar I disorder....
April 22, 2024
Victorita E. Ivan, David P Tomàs-Cuesta, Ingrid M. Esteves et al.
1 citation
Psychedelic drugs have profound effects on perception, cognition, and mood. How psychedelics affect neural signaling to produce these effects remains poorly understood. We investigated the effect of the classic psychedelic psilocybin on neural activity patterns and spatial encoding in the retrosplenial cortex of head-fixed mice navigating on a treadmill. The place specificity of neurons to...
Frontiers in Pharmacology
April 18, 2024
Elad Lerer, Alexander Botvinnik, Orr Shahar et al.
14 citations
Background: Immediate early genes (IEGs) are rapidly activated and initiate diverse cellular processes including neuroplasticity. We report the effect of psilocybin (PSIL), PSIL-containing psychedelic mushroom extract (PME) and 5-hydroxytryptophan (5-HTP) on expression of the IEGs, cfos, egr1 , and egr2 in mouse somatosensory cortex (SSC). Methods: In our initial experiment, male C57Bl/6j mice...
Frontiers in Psychiatry
April 18, 2024
Gina Micciche, Andrew McMillan, Emily Coughlin et al.
4 citations
Introduction Patients with incurable illnesses often experience existential distress, profoundly impacting their well-being. Current medical approaches have limitations in addressing these burdens. Psilocybin, a promising psychedelic compound, may offer therapeutic benefits. This pilot survey study aimed to investigate the attitudes and openness toward psilocybin-assisted psychotherapy (PAT)...